Nuvectis Pharma (NVCT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.30
- Estimate
- -$0.26
- Surprise
- -14.5%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Nuvectis Pharma (NVCT) reported a wider loss than forecast — diluted EPS of -$0.30 against the -$0.26 estimate (a 14.5% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVCT Sell at 5.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -14.5% surprise compares with a -18.5% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: NXP900
- Concentration risk — Counterparty: University of Edinburgh (NXP900 license)
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.56
- Price target
- $29.75
- Stop
- $21.91
- Upside to target
- +26.3%
- Reward-to-risk
- 1.8:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
NVCT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $767.6M
- P/E (fwd)
- -24.5
- 52-week range
- $5.55–$29.27
- Off 52-week high
- 19.5%
- RSI (14)
- 61
- Volume vs avg
- 0.94×
- Score today
- 5.5/10